hims glp-1 results & @Hers sees strong early from its weight loss program. New internal data shows users lost an average of 20.9 pounds in six months, with high adherence and low Hims & Hers Health (HIMS)

doi: 10.1126/science.abe9985

recently demonstrated that thyroid iodide and glucose uptake are influenced by the AMP-activated protein kinase (AMPK) signaling pathway, often referred to as the cellular energy fuel gauge (Skorupa et al., 2021)

The primary endpoint was all-cause mortality, and secondary endpoints were AMI, ischemic stroke, hemorrhagic stroke, atrial fibrillation (A-Fib)/flutter, cardiac arrest, readmission rate, and achievement of HbA1c (blood sugar) levels below 7%

3 Works cited FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize, accessed February 2, 2026, Semaglutide Shortage Resolved McDermott Will & Schulte, accessed February 2, 2026, GLP-1 Update: Court Backs FDA in Tirzepatide Compounding Case, accessed February 2, 2026, The Return of 503B Compounding of GLP-1 Medications Frier Levitt, accessed February 2, 2026, The Strategic Imperative of Pharmaceutical Competitor Analysis: A Comprehensive Guide for 2026 and Beyond DrugPatentWatch, accessed February 2, 2026, Maximizing ROI on Drug Development by Monitoring Competitive Patent Portfolios, accessed February 2, 2026, Compounded Drug Products That Are Essentially Copies of Approved Drug Products Under Section 503B of the Federal Food, Drug, and Cosmetic Act FDA, accessed February 2, 2026, GLP-1 Weight-Loss Drugs Off Shortage List